Upright Revolution: Leo Cancer Care Secures $65M, Reshapes Oncology Landscape
July 9, 2026, 9:31 am
Leo Cancer Care landed $65M Series D funding. The company revolutionizes cancer treatment. It uses an integrated upright platform for radiation therapy and imaging. Patients sit for treatment, enhancing comfort and consistency. This technology dramatically shrinks treatment footprint. It brings advanced care, like proton therapy, to more communities. Funding fuels manufacturing scale and global expansion. Stanford Medicine recently delivered the world's first compact upright proton therapy. A major strategic partnership underscores a paradigm shift in oncology. Leo leads the charge.
Leo Cancer Care dramatically reshapes cancer treatment. The medical technology firm recently secured $65 million in Series D funding. This oversubscribed round marks a significant investment. It fuels a revolutionary approach to oncology. The company focuses on patient-centric care. Its core innovation centers on upright treatment.
The substantial capital injection will accelerate critical initiatives. Manufacturing will scale rapidly. Commercial deployment across global markets will intensify. Clinical and product development also receive a boost. Leo Cancer Care plans to advance its integrated upright platform further. This platform spans proton therapy, photon therapy, and advanced imaging.
Leading the Series D round was Yu Galaxy. Eventide Asset Management joined as a new investor. Existing investors continued their strong support. This broad backing signals immense confidence. The industry sees the transformative potential of upright cancer care.
Leo Cancer Care's vision is clear. It designs systems around the human body's natural upright position. Most of life is spent standing or sitting. Conventional treatments force patients into a supine, or lying down, position. The upright paradigm offers clear advantages. Research indicates improved anatomical positioning. Organ stability during treatment also increases. This can lead to more precise radiation delivery.
The company's innovative Marie® platform stands at the forefront. It represents a paradigm shift in radiotherapy. The system employs a fixed radiation beam. The patient gently rotates while seated. This eliminates the need for massive, multi-tonne gantries. Conventional proton therapy rooms are five times larger. Marie® allows proton therapy in much smaller spaces. Existing radiotherapy vaults can now host advanced proton treatment. This makes specialized care far more accessible.
A historic milestone recently occurred. Stanford Medicine delivered the world's first compact upright proton therapy treatment. This happened on June 4, 2026. A seven-year-old child with a complex brain tumor received the treatment. This event showcased the practical success of Leo's technology. It highlighted the platform's suitability for even the most vulnerable patients.
Clinical adoption is expanding. Beyond Stanford, leading institutions embrace the upright platform. Dana-Farber Cancer Institute and McLaren Health Care are integrating this approach. This adoption spans major academic centers and regional community networks. The innovation reaches diverse healthcare settings.
Leo Cancer Care's upright imaging system already holds FDA clearance. This system is crucial for treatment planning. It also offers future applications in broader radiology settings. A unified architectural approach is a hallmark of Leo's platform. The same upright design applies across imaging, proton therapy, and photon therapy. This creates a seamless continuum of care.
The company's strategic moves extend beyond technology. A major partnership is underway. Leo Cancer Care entered a collaboration with an international healthcare giant. This partnership underscores industry validation. The biggest players now recognize the upright paradigm's value. Details of this collaboration will be announced soon. It signals a major shift in how advanced cancer care is delivered.
This new funding allows Leo to scale its operations globally. The technology will reach more patients in more countries. It empowers communities that previously lacked access to advanced treatments. The focus remains on quality without compromise. The patient-centric design drives this mission.
The integrated platform strategy aims for broader impact. It redefines treatment delivery. It makes advanced care more accessible and sustainable. The potential for cost reduction is significant. Smaller footprints and streamlined processes contribute to efficiency. This approach benefits both patients and healthcare providers.
Leo Cancer Care is based in Middletown, WI, and London, UK. Its global presence continues to grow. The company's vision extends far beyond current capabilities. It aims to integrate advanced diagnostic and therapeutic tools. The upright position forms the foundation of this future. This approach positions Leo as a leader in oncology innovation.
The future of cancer care looks different. It involves patient comfort and precision. It demands expanded access. Leo Cancer Care leads this charge. Its upright platform represents a powerful step forward. The $65 million investment fuels this critical journey. It promises to transform lives worldwide.
Leo Cancer Care dramatically reshapes cancer treatment. The medical technology firm recently secured $65 million in Series D funding. This oversubscribed round marks a significant investment. It fuels a revolutionary approach to oncology. The company focuses on patient-centric care. Its core innovation centers on upright treatment.
The substantial capital injection will accelerate critical initiatives. Manufacturing will scale rapidly. Commercial deployment across global markets will intensify. Clinical and product development also receive a boost. Leo Cancer Care plans to advance its integrated upright platform further. This platform spans proton therapy, photon therapy, and advanced imaging.
Leading the Series D round was Yu Galaxy. Eventide Asset Management joined as a new investor. Existing investors continued their strong support. This broad backing signals immense confidence. The industry sees the transformative potential of upright cancer care.
Leo Cancer Care's vision is clear. It designs systems around the human body's natural upright position. Most of life is spent standing or sitting. Conventional treatments force patients into a supine, or lying down, position. The upright paradigm offers clear advantages. Research indicates improved anatomical positioning. Organ stability during treatment also increases. This can lead to more precise radiation delivery.
The company's innovative Marie® platform stands at the forefront. It represents a paradigm shift in radiotherapy. The system employs a fixed radiation beam. The patient gently rotates while seated. This eliminates the need for massive, multi-tonne gantries. Conventional proton therapy rooms are five times larger. Marie® allows proton therapy in much smaller spaces. Existing radiotherapy vaults can now host advanced proton treatment. This makes specialized care far more accessible.
A historic milestone recently occurred. Stanford Medicine delivered the world's first compact upright proton therapy treatment. This happened on June 4, 2026. A seven-year-old child with a complex brain tumor received the treatment. This event showcased the practical success of Leo's technology. It highlighted the platform's suitability for even the most vulnerable patients.
Clinical adoption is expanding. Beyond Stanford, leading institutions embrace the upright platform. Dana-Farber Cancer Institute and McLaren Health Care are integrating this approach. This adoption spans major academic centers and regional community networks. The innovation reaches diverse healthcare settings.
Leo Cancer Care's upright imaging system already holds FDA clearance. This system is crucial for treatment planning. It also offers future applications in broader radiology settings. A unified architectural approach is a hallmark of Leo's platform. The same upright design applies across imaging, proton therapy, and photon therapy. This creates a seamless continuum of care.
The company's strategic moves extend beyond technology. A major partnership is underway. Leo Cancer Care entered a collaboration with an international healthcare giant. This partnership underscores industry validation. The biggest players now recognize the upright paradigm's value. Details of this collaboration will be announced soon. It signals a major shift in how advanced cancer care is delivered.
This new funding allows Leo to scale its operations globally. The technology will reach more patients in more countries. It empowers communities that previously lacked access to advanced treatments. The focus remains on quality without compromise. The patient-centric design drives this mission.
The integrated platform strategy aims for broader impact. It redefines treatment delivery. It makes advanced care more accessible and sustainable. The potential for cost reduction is significant. Smaller footprints and streamlined processes contribute to efficiency. This approach benefits both patients and healthcare providers.
Leo Cancer Care is based in Middletown, WI, and London, UK. Its global presence continues to grow. The company's vision extends far beyond current capabilities. It aims to integrate advanced diagnostic and therapeutic tools. The upright position forms the foundation of this future. This approach positions Leo as a leader in oncology innovation.
The future of cancer care looks different. It involves patient comfort and precision. It demands expanded access. Leo Cancer Care leads this charge. Its upright platform represents a powerful step forward. The $65 million investment fuels this critical journey. It promises to transform lives worldwide.